Ga]-CDTMP as compared to contralateral tissue was found in PET imaging in Balb/C mice and New Zealand rabbit; the similar result for bone uptake was correlated in the biodistribution study of the compound in BALB/c mice at different time intervals. Biodistribution experiments carried out in mice showed maximum uptake of 6.12 ± 1.22%ID/g at 45 min postinjection. For [ 188 Re]-CDTMP, total skeletal uptake was 8.12 ± 1.11%ID/g observed at 1 h postinjection from biodistribution data. High renal uptake confirms renal route of excretion. A good hydroxyapatite binding too was seen for both the complexes. No evidence of destruction or adverse functioning of vital organs was observed for the 188 Re complex. Ga (68 min), cyclotron-independent radiopharmacy, fast clearance, and rapid renal excretion as evidenced in preclinical animal models. Very low myelotoxicity and highly selective bone uptake prove the potential of [ 
ga, 188 re inTrODUcTiOn Abnormal growth associated with neoplastic conditions, such as anomalous metabolic disorders, contagions, and malignancies result in metastasis in the skeletal tissue. Bone metastasis is prevalent among the majority of patients with metastatic conditions, which results in a high percentage of mortality and morbidity. These skeletal-related events that involve hypercalcemia caused by malignancy, pathological fractures, etc., and thus arises the requirement for surgical intervention or radiation treatment in bone. Published reports indicate toward the early occurrence of bone metastases; a tumor disease, however, the condition remains clinically asymptomatic and is recognized rather late (1, 2) . Bone imaging is one of the medical imaging techniques in nuclear medicine in which whole body metastasis assessment is performed using radiotracers such as [ Radiolabeled phosphonates are of utmost interest in nuclear medicine for metastasis evaluation as well as for therapy as many common tumors are associated with metastasis. Bone-targeting radiopharmaceuticals labeled with β emitters are acceptable adjuvant to external beam therapy for treatment of bone pain in osteoblastic bone metastatic condition. It has been reported that bone pain from metastatic disease occurs more profoundly in patients with malignancies in organs such as prostate, breast, and lung. Bone imaging and bone pain palliation are two distinct procedures followed in nuclear medicine. Phosphonates and phosphonic acids show high affinity for inorganic hydroxide and oxide materials and hence explored as the ideal targeting groups for hydroxyapatite (HAp) and bone. Bisphosphonate moieties radiolabeled with therapeutic isotopes are the category of pharmaceuticals that are widely accepted options for treatment of osteoporosis; a condition associated with an imbalance between osteoblastic and osteoclastic activities. Minimum exposure and maximum resolution, which signify a minimum radiation burden to the patient, as well as minimization of interfering signals in the scintigraphic image, require high specific skeletal uptake of the radiotracer (3). Ga-68-based radiopharmaceuticals for imaging bone thus found interest over 18 F-NaF because of its longer half-life of 110-min and high radiation burden imposed to the patient (4-6). A therapeutic agent employed in radionuclide therapy consists of two components; α particle, β particle or Auger electron-emitting radioisotope and the molecular targeting vector that ensures maximum accumulation at or in desired tumor cells (7) .
Polyphosphonates (PPs) such as MDP (methylenediphosphonate), DPD (3,3-diphosphono-1,2-propandicarboxylic acid), and EDTMP (ethylenediamino-N,N,N′,N′-tetrakismethylenephosphoric acid) are already established as suitable ligands for targeting therapeutic radionuclide into bone tissue (8) ]-fluoride has potential advantages of high sensitivity and increased spatial resolution due to advanced positron emission tomography (PET) technology (11, 12) , thus arises a need for ligand-based tracers with improved diagnostic accuracy for PET application. Apart from 18 F, 68 Ga is another potential radionuclide for PET imaging. Because of advances and commercial availability of 68 Ge/ 68 Ga generators, 68 Ga-radiolabeled PET tracers have found considerable interest. [ 68 Ga]-phosphonates for PET bone imaging earns special mention, because of its easy availability from an in-house generator thus, overcoming the requirement of an on-site cyclotron facility. [ 68 Ga]-labeled phosphonates also prevail over the practical question of higher costs associated with the cyclotron-based production of [ 18 F]-fluoride as compared to a generator-based production and easy radiopharmacy, along with the limitation of on-site cyclotron access. 188 Re is known to possess an excellent therapeutic potential with a short half-life value of 16.9 h, maximum particle energy of 2.1 MeV, and 10 mm of maximum beta range in tissue (13 
MaTerials anD MeThODs chemicals
Trans-1,2-cyclohexyldinitrilotetraaceticacid, monohydrate salt [cyclohexylenedinitrilotetraacetic acid (CDTA)], phosphorous acid, phosphorous trichloride, Na-HEPES buffer [4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid], stannous chloride, methanol, and ethanol (HPLC grade) normal saline were purchased from Sigma-Aldrich Co. 68 Ga used was eluted from in-house Eckert-Ziegler IGG100 (50 mCi) TiO2-based [ 68 Ge] breakthrough <0.001%.
188
Re was procured in readily usable form from Amersham Biosciences. negative ion mode) were performed on in-house Agilent 6310 system ion trap.
animal studies
All the animal studies were done according to approved protocols of Institutional animal ethics committee (CPCSEA Regn No. 8/GO/RBi/S/99). New Zealand white Rabbits (2-3 kg), Wistar rats (200 ± 10 g), and Balb/C mice (25 ± 3 g) were used in experiments. Animals were housed under a controlled temperature condition of 22 ± 2°C and normal diet ad libitum.
PeT imaging experiments
Both PET and MicroPET acquisitions were performed. PET Imaging data were acquired on GE Discovery STE 16 system (PET/CT) system using New Zealand rabbits. PET data were reconstructed using vendor provided ordered-subsets expectation maximization. MicroPET imaging was performed on GE FLEX Triumph MicroPET/SPECT/CT scanner, which consists of a MicroPET module (LabPET 4) with 2 m × 2 m × 10 m, LYSO/
LGSO scintillators in an 8-pixel, quad-APD detector module arrangement. The rabbit was injected intravenously through ear vein whereas mice were injected through the tail vein, and imaging was done 45 min postinjection for [ 68 Ga]-CDTMP. The subject was anesthetized with ketamine (4.8 mg/kg), and midazolam (1.2 mg/kg) administered intramuscularly and was placed prone on PET scanner (37°C). Image reconstruction was done using Amira 4.1.1. Semiquantitative analysis was performed using Amide Software.
sPecT imaging experiment (14) . In brief, to a solution of trans-CDTA (0.5 g, 1.37 mmol) dissolved in 10 mL toluene, phosphorus acid (0.48 g, 6.85 mmol) was added. The mixture was then refluxed at 100°C while phosphorus trichloride (0.75 g, 0.755 mmol) in a volume of 300 mL was added drop wise to the refluxing mixture. After 3 h, the solvent was removed followed by addition of deionized water. The filtrate was concentrated under vacuum. The concentrated product was then precipitated by addition of ethanol to obtain the pure product. The formation of final product CDTMP was confirmed by Mass and NMR spectroscopy.
gallium complexation studies
To a solution of the CDTMP, 25 mg (0.05 mmol) in water was added Ga(NO3)3, 15 mg (0.06 mmol) at pH adjusted to 5.5 using sodium acetate. The reaction mixture was then heated at 90°C and stirred for 8 h. It was then allowed to cool and passed through the C-18 cartridge to remove unreacted species. The mixture was then filtered through a 0.22 μm syringe filter, freeze dried, to yield a white solid with a purity of >95% (15 Ga generator was eluted according to manufacturer protocol (Eckert and Ziegler) with 5 mL of 0.1 N hydrochloric acid (330-520 MBq). 2 mL of above eluate was used for labeling. A stock solution of CDTMP (1 mg/mL water) was prepared, and a 200 µL aliquot was used in labeling studies. Labeling was carried out in Na-HEPES buffer with pH adjusted between 3 and 3.5. The reaction mixture was heated for 10 min at 80°C, passed through C-18 cartridge and eluted with ethanol. Radiolabeling yield was determined by ITLC/SG 1 cm × 8 cm strips (methanol/ammonium acetate 1 M; 1:1) for each step of the experiments. solutions were mixed in a 10 mL vial. To the 0.02 mL of stannous chloride (100 mg/mL in 10% acetic acid), concentrated HCl was added. Under nitrogen, the pH of the reaction mixture was adjusted to 7 with 1 M NaOH. Radiochemical purity of [ 188 Re] complexes was characterized by paper chromatography studies. It is known that using acetone as a solvent in paper chroma tography; the ligand complexes remain at the bottom. Under identical conditions, free 188 
ReO
−4 moved toward the solvent front.
Preclinical studies

HAp Binding Studies
To evaluate HAp binding, 20 mg of synthetic HAp was allowed to incubate in 1 mL of isotonic saline for 24 h. Labeled complex in a volume of 50 µL was then added, subjected to vortex for 10 s and incubated at ambient temperature for 10 min. After incubation, samples had been centrifuged, and the supernatant was removed.
Hap fraction was washed twice with 0.5 mL saline, and all the washes were collected. Radioactivity was then checked in combined liquids and HAp fraction using gamma counter. Ga ]-CDTMP was administered intravenously through the dorsal ear veins of rabbits, and blood samples (200 µL) were withdrawn at different intervals of time. The activity in blood, concerning percentage-administered dose, for different time intervals, was calculated by counting the samples in well counter and time activity curve was generated.
Serum Stability Studies
Serum stability of a radiolabeled pharmaceutical is related to various parameters such as pH, the presence of binding proteins, and metal metabolism. Serum was separated from blood by allowing the blood to clot for 1 h at 37°C in a humidified incubator. Then, the samples were centrifuged at 400 g and plasma separated into sterile tubes. To the 800 µL of serum, 200 µL of the [
68 Ga]-CDTMP complex was added and incubated at 37°C. Free gallium percentage was assessed by ITLC-SG using 1:1 ammonium acetate:methanol as mobile phase at different intervals of time.
Scintigraphy Studies
Scintigraphy studies of both the complexes [ 
Biodistribution Studies
Biodistribution experiments of both [ 
Myelotoxicity Studies
Myelotoxicity studies were performed on male Wistar rats. Myelotoxicity was evaluated by blood cell count (RBC, WBC, and platelets) post 75 MBq [ 188 Re]-CDTMP intravenous injection at selected time points up to 16 days. Blood samples were withdrawn using heparinized capillaries in EDTA coated vials, and blood cell count was recorded on an automatic analyzer (CellTac α MEK6450K, Nihon Kohden).
Decay Correction
All the data including blood clearance studies, biodistribution, and imaging were subjected to decay correction.
resUlTs radiolabeling
Before radiocomplexation of CDTMP, cold complexation of CDTMP was performed with cold gallium nitrate, which was characterized by mass spectroscopy (see Figure S1 in Supplementary Material). Radiochemical yield of [ 68 Ga]-CDTMP was optimized for various conditions of pH, temperature, and compound concentration chromatographically using ITLC-SG (Figure 2) . The optimum pH for labeling was 3-3.5, and deterioration of radiolabeling yield was observed at higher pH. The radiolabeling efficiency was found to be 70 ± 1%. [ 188 Re-CDTMP] too was labeled with radiochemical purity higher than 97 ± 1.2%. It was found that addition of 100 µL of 0.1 M ascorbic acid increases the stability of complex. Radiochemical purity for [ 68 Ga]-CDTMP was assessed using EZ-TLC Scanner (see Figure  S2 in Supplementary Material) Radio-HPLC analysis after tc-18 cartridge purification was performed for [ (Figure 3 ).
Blood Clearance
Blood kinetic studies in rabbits showed that the complex [ images were also obtained (Figures 5 and 6) . Volume of interest analysis of the PET showed a bone to muscle ratio of 21.258 ± 1.3. Semiquantitative analysis of the MicroPET images depicts bone to muscle ratio of 24.146 ± 0.98, bone to kidney ratio of 7.976 ± 0.78. Imaging the [ 68 Ga]-CDTMP uptake in a healthy animals both mice and rabbits showed that the tracer accumulation in bones was prominent. Under physiological conditions, a high activity in the joints was observed. Thus, the [ 
Biodistribution Studies
Biodistribution experiments for [ 68 Ga]-CDTMP carried out in mice showed maximum bone uptake of 6.12 ± 1.22 at 45 min postinjection (Figure 8) . High kidney uptake observed for both the complexes reveals the renal route of excretion. For [ 188 Re]-CDTMP, total skeletal uptake was 8.12 ± 1.11%ID/g observed at 1 h from biodistribution studies (Figure 9) . Biodistribution data for blood for both radiolabeled complexes depict a shorter Rhenium nuclides have γ emissions, which allow for easy detection of distribution pattern and clearance by gamma scintigraphy. The success of the bone pain palliation therapeutic treatment by a particular radiopharmaceutical depends upon the activity administered and percentage uptake of bone. The radioactivity administered and the extent of radiopharmaceutical uptake by bone are the two most important properties considered as the determinants of the success of the treatment with therapeutic radioisotope. To evaluate the skeletal uptake of the radiolabeled phosphonates used in this study, we employed the method that is based on conventional ROI technique and allows compartmental calculation for bone and soft tissue. (28) . The rapid accumulation of agent in bone and high target-to-non-target uptake ratio showed that CDTMP has both therapeutic potential as when coupled to β-emitting radionuclides.
The present study suggests that [ 68 Ga]-labeled CDTMP may serve as a promising vector in nuclear medicine for PET imaging and bone pain palliation with a good bone accumulation property. In vivo PET evaluation revealed predominant uptake in bone with low non-target accumulation and rapid non-osseous clearance. Apart from present assessment, future clinical prospects of [ 68 Ga]-CDTMP require further evaluations and preclinical trials. Moreover, the present study also describes the therapeutic potential of [ 188 Re]-CDTMP as a good therapeutic probe in preclinical studies. Being generator-based radioisotopes 68 Ga and 188 Re have easy availability; single step synthetic strategy of CDTMP both facilitates an on-site simple radiopharmacy with low costs.
eThics sTaTeMenT
This study was carried out in accordance with the recommendations of (CPCSEA Regn No.8/GO/RBi/S/99). The protocol was
